Back to News
Market Impact: 0.1
Immutep Outlines Focused Development Strategy for Eftilagimod Alfa (“efti”)
Source: GlobeNewswire
Healthcare & BiotechCorporate Guidance & Outlook
Immutep announced an update to its development strategy for eftilagimod alfa (efti), its novel immunotherapy candidate. The excerpt provides no clinical data, regulatory milestones, financial details, or revised development timelines, limiting the immediate market significance.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.00
Ticker Sentiment
IMMP0.10
More News
- Apollo in talks to buy J&J orthopedics unit for nearly $20 billion
- Surging cloud revenue boosted Oracle’s quarterly results. Here’s what analysts are saying
- Oracle jumps 6% after reporting 30% revenue growth fueled by AI cloud demand
- Apollo Global in talks to acquire J&J’s orthopedics unit, Bloomberg News reports
- Oracle’s AI Cloud Growth Eases Buildout Concerns
- U.S. CPI looms large; Oracle, Adobe report - what’s moving markets